AU2017347725B2 - Recombinant virus replicon systems and uses thereof - Google Patents

Recombinant virus replicon systems and uses thereof Download PDF

Info

Publication number
AU2017347725B2
AU2017347725B2 AU2017347725A AU2017347725A AU2017347725B2 AU 2017347725 B2 AU2017347725 B2 AU 2017347725B2 AU 2017347725 A AU2017347725 A AU 2017347725A AU 2017347725 A AU2017347725 A AU 2017347725A AU 2017347725 B2 AU2017347725 B2 AU 2017347725B2
Authority
AU
Australia
Prior art keywords
nucleic acid
modified
acid molecule
rna
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017347725A
Other languages
English (en)
Other versions
AU2017347725A1 (en
Inventor
Kurt Iver Kamrud
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceuticals Inc
Original Assignee
Janssen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceuticals Inc filed Critical Janssen Pharmaceuticals Inc
Publication of AU2017347725A1 publication Critical patent/AU2017347725A1/en
Assigned to Janssen Pharmaceuticals, Inc. reassignment Janssen Pharmaceuticals, Inc. Request for Assignment Assignors: SYNTHETIC GENOMICS, INC.
Application granted granted Critical
Publication of AU2017347725B2 publication Critical patent/AU2017347725B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2017347725A 2016-10-17 2017-10-03 Recombinant virus replicon systems and uses thereof Active AU2017347725B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662409228P 2016-10-17 2016-10-17
US62/409,228 2016-10-17
PCT/US2017/054928 WO2018075235A1 (en) 2016-10-17 2017-10-03 Recombinant virus replicon systems and uses thereof

Publications (2)

Publication Number Publication Date
AU2017347725A1 AU2017347725A1 (en) 2019-05-09
AU2017347725B2 true AU2017347725B2 (en) 2024-01-04

Family

ID=60153459

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017347725A Active AU2017347725B2 (en) 2016-10-17 2017-10-03 Recombinant virus replicon systems and uses thereof

Country Status (10)

Country Link
US (2) US11364310B2 (OSRAM)
EP (1) EP3526332B1 (OSRAM)
JP (2) JP7382230B2 (OSRAM)
KR (1) KR102718353B1 (OSRAM)
CN (1) CN110073002B (OSRAM)
AU (1) AU2017347725B2 (OSRAM)
BR (1) BR112019007433A2 (OSRAM)
ES (1) ES2993107T3 (OSRAM)
MX (1) MX2019004499A (OSRAM)
WO (1) WO2018075235A1 (OSRAM)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3443107A1 (en) 2016-04-13 2019-02-20 Synthetic Genomics, Inc. Recombinant arterivirus replicon systems and uses thereof
WO2018075235A1 (en) 2016-10-17 2018-04-26 Synthetic Genomics, Inc. Recombinant virus replicon systems and uses thereof
EP3548625B1 (en) 2016-12-05 2024-06-26 Janssen Pharmaceuticals, Inc. Compositions and methods for enhancing gene expression
US11021692B2 (en) 2017-12-19 2021-06-01 Janssen Sciences Ireland Unlimited Company Hepatitis B virus (HBV) vaccines and uses thereof
EA202091517A1 (ru) 2017-12-19 2020-11-03 Янссен Сайенсиз Айрлэнд Анлимитед Компани Способы и устройство для доставки вакцин против вируса гепатита b (hbv)
US11020476B2 (en) 2017-12-19 2021-06-01 Janssen Sciences Ireland Unlimited Company Methods and compositions for inducing an immune response against Hepatitis B Virus (HBV)
BR112020014525A2 (pt) 2018-01-19 2020-12-08 Janssen Pharmaceuticals, Inc. Induzir e intensificar respostas imunes utilizando sistemas de replicon recombinantes
AU2019222560B2 (en) 2018-02-17 2025-07-03 Flagship Pioneering Innovations V, Inc. Compositions and methods for membrane protein delivery
MX2021004032A (es) 2018-10-08 2021-07-06 Janssen Pharmaceuticals Inc Replicones basados en alfavirus para la administracion de bioterapeuticos.
CN113631718A (zh) 2018-11-14 2021-11-09 旗舰先锋创新V股份有限公司 用于特定隔室货物递送的组合物和方法
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
US20220313815A1 (en) * 2019-06-20 2022-10-06 Janssen Sciences Ireland Unlimited Company Self-replicating rna molecules for hepatitis b virus (hbv) vaccines and uses thereof
US11679163B2 (en) 2019-09-20 2023-06-20 Hdt Bio Corp. Compositions and methods for delivery of RNA
CA3161800A1 (en) 2019-11-18 2021-05-27 Janssen Biotech, Inc. Vaccines based on mutant calr and jak2 and their uses
AU2020417800A1 (en) 2019-12-31 2022-07-14 Elixirgen Therapeutics, Inc. Temperature-based transient delivery of nucleic acids and proteins to cells and tissues
TW202144388A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在卵巢癌中表現之新抗原及其用途
TW202144389A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在多發性骨髓瘤中表現之新抗原及其用途
US11744887B2 (en) 2020-03-09 2023-09-05 Arcturus Therapeutics, Inc. Coronavirus vaccine compositions and methods
KR20210116324A (ko) 2020-03-12 2021-09-27 기초과학연구원 게놈 서열 변이를 가지는 세포 사멸 유도용 조성물 및 상기 조성물을 이용한 세포 사멸 유도 방법
JP2023518976A (ja) 2020-03-23 2023-05-09 エイチディーティー バイオ コーポレーション Ｒｎａを送達するための組成物および方法
EP4135757A1 (en) 2020-04-13 2023-02-22 Janssen Biotech, Inc. Psma and steap1 vaccines and their uses
CA3183500A1 (en) 2020-05-11 2021-11-18 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
BR112022022942A2 (pt) 2020-05-11 2022-12-13 Janssen Pharmaceuticals Inc Réplicon de rna que codifica uma proteína spike de coronavírus estabilizada
US20230035403A1 (en) 2020-07-06 2023-02-02 Janssen Biotech, Inc. Method For Determining Responsiveness To Prostate Cancer Treatment
WO2022009052A2 (en) 2020-07-06 2022-01-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
EP4175721A1 (en) 2020-07-06 2023-05-10 Janssen Biotech, Inc. Prostate neoantigens and their uses
EP4178613A1 (en) 2020-07-08 2023-05-17 Janssen Sciences Ireland Unlimited Company Rna replicon vaccines against hbv
AU2021315795A1 (en) * 2020-07-31 2023-02-23 Replicate Bioscience, Inc. Modified Chikungunya viruses and Sindbis viruses and uses thereof
AU2021325945A1 (en) 2020-08-14 2023-04-06 Arcturus Therapeutics, Inc. Method of lyophilizing lipid nanoparticles
CN112458064A (zh) * 2020-11-20 2021-03-09 广西大学 盖他病毒全长感染性克隆、复制子系统及其制备和应用
WO2022133230A1 (en) 2020-12-18 2022-06-23 Janssen Pharmaceuticals, Inc. Combination therapy for treating hepatitis b virus infection
CN112852841A (zh) * 2021-02-03 2021-05-28 郑州大学 一种高效表达目的蛋白的顺式复制子rna构建体
KR20240032932A (ko) * 2021-07-09 2024-03-12 레플리케이트 바이오사이언스, 인크. 변형된 동부 말 뇌염 바이러스, 자가-복제 rna 작제물, 및 이의 용도
KR20240111819A (ko) 2021-09-22 2024-07-17 에이치디티 바이오 코포레이션 암 치료 조성물 및 이들의 용도
KR20240099177A (ko) 2021-09-22 2024-06-28 에이치디티 바이오 코포레이션 SARS-CoV-2 RNA 백신 조성물 및 사용 방법
WO2023048758A1 (en) 2021-09-22 2023-03-30 Hdt Bio Corp. Dried nanoparticle compositions
AU2022351009A1 (en) 2021-09-22 2024-04-11 Hdt Bio Corp. Rna vaccines against infectious diseases
GEAP202516650A (en) 2022-05-12 2025-03-10 Msd Int Business Gmbh Stabilized pre-fusion hmpv fusion proteins
WO2024008192A2 (zh) * 2022-07-08 2024-01-11 嘉晨西海(杭州)生物技术有限公司 经修饰的自复制mRNA
WO2025088152A1 (en) 2023-10-27 2025-05-01 Ziphius Nv MODIFIED 5'UTRs

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014170493A2 (en) * 2013-04-19 2014-10-23 Novartis Ag Alphavirus vector

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU561343B2 (en) 1981-10-19 1987-05-07 Genentech Inc. Human immune interferon by recombinant dna
US4738927A (en) 1982-03-31 1988-04-19 Ajinomoto Co. Inc. Gene coded for interleukin-2 polypeptide, recombinant DNA carrying the said gene, a living cell line possessing the recombinant DNA, and method for producing interleukin-2 using the said cell
US4966843A (en) 1982-11-01 1990-10-30 Cetus Corporation Expression of interferon genes in Chinese hamster ovary cells
US4892743A (en) 1983-12-21 1990-01-09 Schering Corporation Novel hybrid interferon species
EP0165942A1 (en) 1983-12-23 1986-01-02 Monash University PRODUCTION OF HUMAN INTERFERON-$g(a)
AU594014B2 (en) 1984-03-21 1990-03-01 Research Corporation Technologies, Inc. Recombinant DNA molecules
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
JPS63500636A (ja) 1985-08-23 1988-03-10 麒麟麦酒株式会社 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ
US5017691A (en) 1986-07-03 1991-05-21 Schering Corporation Mammalian interleukin-4
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
EP0446283A4 (en) 1988-12-01 1992-01-08 Univ North Carolina Synthetic interleukin-6
US5225337A (en) 1989-09-25 1993-07-06 Innovir Laboratories, Inc. Ribozyme compositions and methods for use
US5246921A (en) 1990-06-26 1993-09-21 The Wistar Institute Of Anatomy And Biology Method for treating leukemias
US5780036A (en) 1991-08-26 1998-07-14 The Scripps Research Institute Peptides for inducing cytotoxic T lymphocyte responses to hepattis B virus
AU702367B2 (en) 1993-08-02 1999-02-18 Scripps Research Institute, The Peptides for inducing cytotoxic T lymphocyte responses to hepatitis B virus
SE9401709D0 (sv) 1994-05-18 1994-05-18 Mathilda Sjoeberg Improved alphavirus vectors for expression of heterologous DNA
US5792462A (en) 1995-05-23 1998-08-11 University Of North Carolina At Chapel Hill Alphavirus RNA replicon systems
US6041252A (en) 1995-06-07 2000-03-21 Ichor Medical Systems Inc. Drug delivery system and method
DE19712889A1 (de) 1997-03-27 1998-10-01 Bosch Gmbh Robert Verfahren und Vorrichtung zur Ermittlung einer den Systemdruck in einem Bremskreis beschreibenden Größe
US6261281B1 (en) 1997-04-03 2001-07-17 Electrofect As Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
CA2285056C (en) 1997-04-03 2004-12-14 Iacob Mathiesen Method for introducing pharmaceutical drugs and nucleic acids into skeletal muscle
US5873849A (en) 1997-04-24 1999-02-23 Ichor Medical Systems, Inc. Electrodes and electrode arrays for generating electroporation inducing electrical fields
GB0023203D0 (en) 2000-09-21 2000-11-01 Isis Innovation Vaccination method
US6117660A (en) 1997-06-10 2000-09-12 Cytopulse Sciences, Inc. Method and apparatus for treating materials with electrical fields having varying orientations
JP2002507985A (ja) 1997-06-30 2002-03-12 ローヌ−プーラン・ロレ・エス・アー 横紋筋に核酸を導入する改良法およびその組合せ
US5958060A (en) 1998-01-02 1999-09-28 General Electric Company Method and apparatus for clock control and synchronization
US6697669B2 (en) 1998-07-13 2004-02-24 Genetronics, Inc. Skin and muscle-targeted gene therapy by pulsed electrical field
US6319901B1 (en) 1998-10-15 2001-11-20 Ichor Medical Systems, Inc. Methods for prolonging cell membrane permeability
US20040213805A1 (en) 1999-10-12 2004-10-28 Verheije Monique Helene Deletions in arterivirus replicons
WO2002020721A2 (en) 2000-09-07 2002-03-14 University Of North Carolina At Chapel Hill Vectors derived from south african arbovirus no. 86
US6538922B1 (en) 2000-09-27 2003-03-25 Sandisk Corporation Writable tracking cells
AU3163902A (en) 2000-11-23 2002-06-03 Bavarian Nordic Res Inst As Modified vaccinia ankara virus variant
AU2002242016A1 (en) 2001-02-01 2002-08-12 The Johns Hopkins University Nucleic acid derived vaccine that encodes an antigen linked to a polypeptide that promotes antigen presentation
ATE354260T1 (de) 2001-07-19 2007-03-15 Ericsson Telefon Ab L M Verfahren und vorrichtung für die lösung der nummernübertragbarkeit am ursprungsort
US8209006B2 (en) 2002-03-07 2012-06-26 Vgx Pharmaceuticals, Inc. Constant current electroporation device and methods of use
US7245963B2 (en) 2002-03-07 2007-07-17 Advisys, Inc. Electrode assembly for constant-current electroporation and use
US6912417B1 (en) 2002-04-05 2005-06-28 Ichor Medical Systmes, Inc. Method and apparatus for delivery of therapeutic agents
US7328064B2 (en) 2002-07-04 2008-02-05 Inovio As Electroporation device and injection apparatus
AU2003297860A1 (en) 2002-12-12 2004-07-09 The Board Of Regents Of The University Of Texas System Large scale production of packaged alphavirus replicons
US8080255B2 (en) 2003-07-11 2011-12-20 Novavax Inc. Functional influenza virus like particles (VLPs)
EP1651666B1 (en) 2003-07-11 2009-05-27 Alphavax, Inc. Alphavirus-based cytomegalovirus vaccines
US20050070700A1 (en) 2003-09-30 2005-03-31 Matthias Giese Equine arteritis virus vaccine
NZ550342A (en) 2004-03-08 2010-06-25 Ichor Medical Systems Inc Improved apparatus for electrically mediated delivery of therapeutic agents
US8859198B2 (en) 2006-06-06 2014-10-14 Abl Sa Detection and use of antiviral resistance mutations
EP2062246A4 (en) * 2006-08-18 2010-09-29 Univ North Carolina VACCINES AGAINST CHIMARICAL VIRUSES
US9452285B2 (en) 2006-10-17 2016-09-27 Vgx Pharmaceuticals, Inc. Electroporation devices and methods of using same for electroporation of cells in mammals
US20090018031A1 (en) 2006-12-07 2009-01-15 Switchgear Genomics Transcriptional regulatory elements of biological pathways tools, and methods
KR100836745B1 (ko) 2007-01-31 2008-06-10 (주)두비엘 Ｈｂｖ 백신 및 그의 제조 방법
PL2183368T3 (pl) * 2007-06-21 2016-12-30 Kasety bez promotora do ekspresji alfawirusowych białek strukturalnych
WO2009056535A2 (en) 2007-10-29 2009-05-07 Genimmune N.V. Methods and kits for inducing a ctl response using a prime boost regimen
SG178254A1 (en) 2009-08-07 2012-03-29 Transgene Sa Composition for treating hbv infection
WO2011082388A2 (en) 2009-12-31 2011-07-07 Medigen, Inc . Infectious dna vaccines against chikungunya virus
PL3243526T3 (pl) 2010-07-06 2020-05-18 Glaxosmithkline Biologicals S.A. Dostarczanie rna w celu wyzwolenia wielu szlaków immunologicznych
EP2655621B1 (en) 2010-12-20 2018-05-23 The General Hospital Corporation Polycomb-associated non-coding rnas
ES2806263T3 (es) 2011-02-11 2021-02-17 Univ Pennsylvania Molécula de ácido nucleico que codifica la proteína del núcleo del virus de la hepatitis b y vacuna que comprende la misma
CN103687644B (zh) 2011-06-28 2016-11-09 艾诺奥医药品有限公司 微创性皮肤电穿孔装置
TWI575070B (zh) 2011-07-12 2017-03-21 傳斯堅公司 Ｈｂｖ聚合酶突變體
US8961995B2 (en) * 2012-09-20 2015-02-24 Uab Research Foundation Methods and compositions for alphavirus replicons
EP2932993B1 (en) 2012-12-13 2017-03-29 Panasonic Healthcare Holdings Co., Ltd. Medicament injection device
AU2014310935B2 (en) 2013-08-21 2019-11-21 CureVac SE Combination vaccine
WO2016020538A1 (en) 2014-08-08 2016-02-11 Transgene Sa Hbv vaccine and antibody combination therapy to treat hbv infections
CA2962799A1 (en) 2014-10-01 2016-04-07 The Trustees Of The University Of Pennsylvania Vaccines having an antigen and interleukin-21 as an adjuvant
PT3280729T (pt) 2015-04-08 2022-08-01 Novartis Ag Terapias para cd20, terapias para cd22 e terapias de combinação com uma célula que expressa o recetor de antigénio quimérico (car) para cd19
ES2875589T3 (es) 2015-05-15 2021-11-10 Curevac Ag Regímenes de sensibilización-refuerzo que implican la administración de al menos un constructo de ARNm
AU2016302237B2 (en) 2015-08-03 2022-08-04 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Brachyury deletion mutants, non-yeast vectors encoding brachyury deletion mutants, and their use
WO2017059902A1 (en) * 2015-10-07 2017-04-13 Biontech Rna Pharmaceuticals Gmbh 3' utr sequences for stabilization of rna
SG11201808236YA (en) 2016-03-28 2018-10-30 Ichor Medical Systems Inc Method and apparatus for delivery of therapeutic agents
US11324819B2 (en) 2016-04-06 2022-05-10 University Of Washington Therapeutic vaccine for Hepatitis b virus (HBV) using the HBV core antigen
EP3443107A1 (en) 2016-04-13 2019-02-20 Synthetic Genomics, Inc. Recombinant arterivirus replicon systems and uses thereof
WO2018075235A1 (en) 2016-10-17 2018-04-26 Synthetic Genomics, Inc. Recombinant virus replicon systems and uses thereof
EP3548625B1 (en) 2016-12-05 2024-06-26 Janssen Pharmaceuticals, Inc. Compositions and methods for enhancing gene expression
JP6613399B2 (ja) 2017-06-05 2019-12-04 株式会社ビークル Ｈｂｖに対する免疫応答を生じさせるために用いられるウイルス様粒子
CN111542340B (zh) 2017-11-16 2023-12-19 华盛顿大学 治疗性乙型肝炎病毒(hbv)疫苗
CN111836641A (zh) 2017-12-19 2020-10-27 杨森科学爱尔兰无限公司 乙型肝炎病毒(hbv)疫苗及其用途
BR112020014525A2 (pt) * 2018-01-19 2020-12-08 Janssen Pharmaceuticals, Inc. Induzir e intensificar respostas imunes utilizando sistemas de replicon recombinantes

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014170493A2 (en) * 2013-04-19 2014-10-23 Novartis Ag Alphavirus vector

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
R. KULASEGARAN-SHYLINI ET AL: "Structural and Functional Elements of the Promoter Encoded by the 5' Untranslated Region of the Venezuelan Equine Encephalitis Virus Genome", Journal of Virology, 2009, vol. 83, no. 17, pages 8327 - 8339 *

Also Published As

Publication number Publication date
EP3526332B1 (en) 2024-06-26
AU2017347725A1 (en) 2019-05-09
KR102718353B1 (ko) 2024-10-15
EP3526332C0 (en) 2024-06-26
BR112019007433A2 (pt) 2019-07-02
US20230126773A1 (en) 2023-04-27
JP2023134488A (ja) 2023-09-27
EP3526332A1 (en) 2019-08-21
CN110073002B (zh) 2024-06-11
JP2019530466A (ja) 2019-10-24
CA3040264A1 (en) 2018-04-26
CN110073002A (zh) 2019-07-30
MX2019004499A (es) 2019-11-18
WO2018075235A1 (en) 2018-04-26
ES2993107T3 (en) 2024-12-23
US11364310B2 (en) 2022-06-21
US20180104359A1 (en) 2018-04-19
KR20190082226A (ko) 2019-07-09
JP7382230B2 (ja) 2023-11-16

Similar Documents

Publication Publication Date Title
US20230126773A1 (en) Recombinant virus replicon systems and uses thereof
US20240209379A1 (en) Compositions and methods for enhancing gene expression
AU699384B2 (en) Alphavirus cDNA vectors
JP5727420B2 (ja) アルファウイルス粒子及び調製方法
JPH11505719A (ja) アルファウイルスｒｎａレプリコン系
JPH10500017A (ja) アルファウイルス発現ベクター
Volkova et al. IRES-dependent replication of Venezuelan equine encephalitis virus makes it highly attenuated and incapable of replicating in mosquito cells
CA3040264C (en) Recombinant virus replicon systems and uses thereof
Schlesinger Alphavirus expression vectors
AU753729B2 (en) Alphavirus vectors
US20080096274A1 (en) Recombinant alphavirus vectors and methods of using same
WO2024133550A1 (en) Eukaryotic self-amplifying system
WO2023147498A1 (en) Methods for generating functional self-replicating rna molecules
Polo et al. Sindbis virus-based vectors for the study of class I antigen presentation in vitro and in vivo
MXPA00004707A (es) Vectores de alfa virus

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: JANSSEN PHARMACEUTICALS, INC.

Free format text: FORMER APPLICANT(S): SYNTHETIC GENOMICS, INC.

FGA Letters patent sealed or granted (standard patent)